Drug intelligence / Profile preview

KY007

Development stage: Preclinical
Lead developer: KYDES Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

KY007 (also known as KY1107) is an investigational oral abuse-deterrent formulation (ADF) developed by KYDES Pharmaceuticals. It is designed for the management of severe pain while mitigating the risks associated with opioid abuse, addiction, and overdose. The formulation utilizes a patentable technology to deter common methods of tampering or misuse, although the specific chemical or physical mechanism of deterrence has not been publicly disclosed. It is currently in the development stage.

Targets

DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on KY007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KY007.

Explore the full profile